TITLE

News in brief

AUTHOR(S)
Aldrige, Susan; DeFrancesco, Laura; Fox, Jeffrey L.; Huggett, Brandy; Hepeng Jia; Kling, Jim; Katsnelson, Alla
PUB. DATE
March 2007
SOURCE
Nature Biotechnology;Mar2007, Vol. 25 Issue 3, p269
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on developments related to biotechnology in the United States as of March 2007. The National Science Foundation has allocated funds for plant genome research. Judge Henry Kennedy of the District Court of Washington has ruled in favor of environmental groups who opposed field trials involving genetically engineered turf grasses. San Francisco, California-based Exelixis has closed two deals on drugs scheduled for clinical trials.
ACCESSION #
24279327

 

Related Articles

  • Antisoma AML Product Records Strong Response. Moran, Nuala // BioWorld International;12/10/2008, Vol. 13 Issue 50, p7 

    The article reports on the announcement of Antisoma plc regarding the positive data from an ongoing Phase II study of its aptamer drug, AS1411 in relapsed and refractory acute myeloid leukemia (AML). Data showed that 16 percent or three out of the nineteen patients responded to the drug. The...

  • Biotech grows, pharmacies must adapt.  // Drug Store News;9/27/2004, Vol. 26 Issue 12, p22 

    Reports on the growth of the biotechnology drugs under clinical trials in the U.S. Transformation of medicine from treatment to prevention; Creation of new challenges and opportunities for retail pharmacy; Success of the scientists in mapping the human genome.

  • News Update.  // Applied Clinical Trials;Oct2002, Vol. 11 Issue 10, p14 

    Presents news briefs related to clinical trials as of October 2002. U.S. Food and Drug Administration's reevaluation of the responsibilities of its Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research; Japan-based Yamanouchi Pharmaceutical Co. Ltd's...

  • How to join a clinical trial--and avoid the tribulations. Lipman, Marvin M. // Consumer Reports on Health;Aug94, Vol. 6 Issue 8, p94 

    Discusses the conduct of clinical trials for new drugs and medical procedures. Experiences with clinical trials; Establishment of cause and effect; Random assignment and double blind method; Factors that influence volunteers to participate in experimental therapies.

  • Adefovir Dipivoxil: Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA.  // Drugs in R&D;2002, Vol. 3 Issue 3, p178 

    Adis CommentsAdefovir dipivoxil [GS 840, bis-POM PMEA, Piv2PMEA] is an ester prodrug of the nucleoside reverse transcriptase inhibitor adefovir, the prototype compound of the acyclic nucleosides phosphonates (ANP) class. This profile has been selected from R&D Insightâ„¢, a pharmaceutical...

  • Profile Summary.  // Drugs in R&D;2002, Vol. 3 Issue 3, p177 

    All drugs appearing in the Adis Profile Summary table have been selected based on information contained in R&D Insightâ„¢, a proprietary product of Adis International. The information in the profiles is gathered from the world's medical and scientific literature, at international conferences...

  • Registering clinical trials. Tonks, Alison // BMJ: British Medical Journal (International Edition);12/11/99, Vol. 319 Issue 7224, p1565 

    Focuses on the importance of registering clinical trials. Aim of registering a clinical trial of a new drug or intervention; Why trials are registered; Details on the duties of the clinical trial registers; Barriers to unifying trial registration across the world.

  • Neurologix initiates Phase II Parkinson's disease trial.  // PharmaWatch: CNS;Mar2009, Vol. 8 Issue 3, p8 

    The article reports on the initiation of Phase II Parkinson's disease trial by Neurologix Inc., a biotechnology company. It states that the participants in the first trial have undergone surgery at multiple institutions and additional subjects are being enrolled. It notes that the trial aims to...

  • Sizing Up Scanning Electron Microscopy. May, Mike // Drug Discovery & Development;Nov2011, Vol. 14 Issue 11, p28 

    The article reports on the trends in scanning electron microscopy (SEM) in the U.S. pharmaceutical and biotechnology industries. The author mentions that SEM is used by contract research organizations (CROs) in helping their clients come up with drug formulations and in clinical trials. He adds...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics